What a Blood Test for Depression Means for Providers
Our diagnostic will bring unprecedented clarity in treating depression, with the ability to quantify your patient's condition, set a numerical therapeutic goal, and monitor your patient's journey toward that goal. While it can take patients an agonizing month or more to determine whether a treatment is working, the MoodMark® diagnostic will do this the first week, sparing patients weeks of uncertainty and unnecessary side effects.
A biological determination of severity of depression will help providers determine the appropriate level of intervention, particularly in justifying treatments that are especially time- and/or cost-intensive, and help patients to understand an objective basis for such decisions.
With our predictive test, our diagnostic will measure the effects of different compounds on the patient's blood sample, potentially avoiding years of failure with pharmaceutical approaches that could have been determined as ineffective before prescribing, and bringing the patient an effective treatment from there start. Providers will be able to gauge the necessity of modifications to dosage, or addition of complementary treatment, at an early stage, rather than wait until the patient has already lost faith in the treatment plan.
Deployed by providers at scale, we will be able to screen populations of patients at high risk of untreated depression (like military and their families, students, people with disabilities, life-threatening diseases, severe physical pain, and people in under-treated communities), and bring millions of suffering people being missed by self-reporting the help they need.
Together, we will reduce the prevalence of three problems in depression treatment.
Depressed individuals who could benefit from treatment but are missed by surveys, or by their healthcare providers' lack of time or information necessary to assess them, or dismiss their own depression as something happening "all in their head" rather than, as we can show them, something happening even in their blood
Individuals who may fleetingly or persistently identify with certain symptoms of depression but do not have the cellular activity of depression, whose mood is unnecessarily brought into a medical context, who endure the negative side effects of treatments and of withdrawals without proper need or benefit
Patients with, for example, bipolar disorder, schizophrenia, PTSD, substance use disorders, Lyme disease, chronic fatigue syndrome, hormonal or vitamin deficiencies, whose actual condition is missed when similar reported symptoms suggest depression, and which in some cases may be worsened by the effects or side effects of a misadvised anti-depressant treatment (such as a triggering of mania, psychosis, or increased suicidal ideation in patients with other mental illness, or rapid weight gain exacerbating physical conditions)